Organigram (TSE:OGI) Price Target Cut to C$3.25 by Analysts at Atb Cormark Cm

Organigram (TSE:OGIFree Report) had its price target trimmed by Atb Cormark Cm from C$3.50 to C$3.25 in a research note published on Wednesday, MarketBeat.com reports. The firm currently has an outperform rating on the stock.

Separately, Canaccord Genuity Group set a C$3.00 target price on shares of Organigram and gave the company a “buy” rating in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of C$3.13.

Check Out Our Latest Analysis on Organigram

Organigram Trading Down 6.9%

Organigram stock opened at C$1.76 on Wednesday. Organigram has a 52-week low of C$1.22 and a 52-week high of C$3.09. The company has a market cap of C$236.65 million, a P/E ratio of -9.07, a P/E/G ratio of 0.42 and a beta of 1.97. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07. The business has a 50-day simple moving average of C$2.30 and a two-hundred day simple moving average of C$2.30.

About Organigram

(Get Free Report)

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Read More

Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.